Logo image of XXII

22ND CENTURY GROUP INC (XXII) Stock Fundamental Analysis

NASDAQ:XXII - US90137F4000 - Common Stock

1.8594 USD
+0.01 (+0.51%)
Last: 8/27/2025, 3:09:41 PM
Fundamental Rating

2

XXII gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 8 industry peers in the Tobacco industry. While XXII seems to be doing ok healthwise, there are quite some concerns on its profitability. XXII is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XXII had negative earnings in the past year.
XXII had a negative operating cash flow in the past year.
In the past 5 years XXII always reported negative net income.
XXII had a negative operating cash flow in each of the past 5 years.
XXII Yearly Net Income VS EBIT VS OCF VS FCFXXII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

XXII has a Return On Assets of -99.71%. This is amonst the worse of the industry: XXII underperforms 87.50% of its industry peers.
Looking at the Return On Equity, with a value of -396.39%, XXII is doing worse than 62.50% of the companies in the same industry.
Industry RankSector Rank
ROA -99.71%
ROE -396.39%
ROIC N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXII Yearly ROA, ROE, ROICXXII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

XXII does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXII Yearly Profit, Operating, Gross MarginsXXII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XXII has been increased compared to 1 year ago.
Compared to 5 years ago, XXII has more shares outstanding
The debt/assets ratio for XXII has been reduced compared to a year ago.
XXII Yearly Shares OutstandingXXII Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
XXII Yearly Total Debt VS Total AssetsXXII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -26.10, we must say that XXII is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XXII (-26.10) is worse than 62.50% of its industry peers.
XXII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.1
ROIC/WACCN/A
WACC7.41%
XXII Yearly LT Debt VS Equity VS FCFXXII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.77 indicates that XXII may have some problems paying its short term obligations.
XXII's Current ratio of 0.77 is on the low side compared to the rest of the industry. XXII is outperformed by 75.00% of its industry peers.
XXII has a Quick Ratio of 0.77. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.61, XXII is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.61
XXII Yearly Current Assets VS Current LiabilitesXXII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 98.90% over the past year.
The Revenue for XXII has decreased by -32.51% in the past year. This is quite bad
XXII shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.15% yearly.
EPS 1Y (TTM)98.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3680.56%
Revenue 1Y (TTM)-32.51%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-48.64%

3.2 Future

XXII is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.81% yearly.
The Revenue is expected to grow by 24.06% on average over the next years. This is a very strong growth
EPS Next Y5.25%
EPS Next 2Y41.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.73%
Revenue Next 2Y24.06%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XXII Yearly Revenue VS EstimatesXXII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
XXII Yearly EPS VS EstimatesXXII Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 0 -100K -200K -300K

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

XXII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.29, the valuation of XXII can be described as reasonable.
XXII's Price/Forward Earnings ratio is rather cheap when compared to the industry. XXII is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.67. XXII is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 8.29
XXII Price Earnings VS Forward Price EarningsXXII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXII Per share dataXXII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K -2K

4.3 Compensation for Growth

XXII's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as XXII's earnings are expected to grow with 41.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.81%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

XXII does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

22ND CENTURY GROUP INC

NASDAQ:XXII (8/27/2025, 3:09:41 PM)

1.8594

+0.01 (+0.51%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners2.2%
Inst Owner Change-86.88%
Ins Owners14.6%
Ins Owner Change0.49%
Market Cap6.53M
Analysts82.86
Price Target64.52 (3369.94%)
Short Float %3.86%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-148.29%
Min EPS beat(2)-181.72%
Max EPS beat(2)-114.86%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-26.42%
Max Revenue beat(2)24.24%
Revenue beat(4)1
Avg Revenue beat(4)-22.45%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)24.24%
Revenue beat(8)1
Avg Revenue beat(8)-24.92%
Revenue beat(12)2
Avg Revenue beat(12)-26.25%
Revenue beat(16)3
Avg Revenue beat(16)-19.83%
PT rev (1m)0%
PT rev (3m)427.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-777.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.29
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2190.45
EYN/A
EPS(NY)0.22
Fwd EY12.07%
FCF(TTM)-3.99
FCFYN/A
OCF(TTM)-3.94
OCFYN/A
SpS5.7
BVpS1.6
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.71%
ROE -396.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.83%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.61
Altman-Z -26.1
F-Score4
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)104.4%
Cap/Depr(5y)87.56%
Cap/Sales(3y)9.68%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3680.56%
EPS Next Y5.25%
EPS Next 2Y41.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.51%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-48.64%
Revenue Next Year-12.73%
Revenue Next 2Y24.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.74%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.04%
OCF growth 3YN/A
OCF growth 5YN/A